… the challenges for the clinical development of triple and multidrug anti-malarial combination
therapies and the hard choices that need to be taken in the further clinical evaluation and …

… This review discusses challenges and potential solutions for … and phosphatidylinositol
3-kinase [PI3K]/AKT pathways in … the combination without large randomized clinical trials that …

… targets, and drug combinations will be required. Delivering … The linear drug development
process, with three distinct … of the prevailing issues in drug development—issues central to the …

… clinical trials are needed to prove that drug combinations identified … In our mind, three major
challenges face the clinical … full-dose combinations of MEK and PI3K pathway inhibitors has …

… MK-0752 in combination with chemotherapy or hormonal therapy is currently evaluated in
… complex optimizing process of drug dosing schedules. The intermittent schedule with 3 days …

… For two of the three breast cancer subtypes, the ER/PR- and … , we have a combination of a
targeted drug and a predictive … at present >800 drugs are in clinical development for cancer …

… Several clinical trials combined MAPK pathway inhibitors … Some clinical trials also empirically
formulate drug combinations … [114] of current drug combinations in clinical trials and patient-…

… This review discusses these challenges, as well as potential … even from double or triple
combinations of novel agents with or … clinical development is in earlier stages. Some agents hit …

… potential benefit in cancer care [3-8], the design, … combination attractive in settings of more
limited resources. Nevertheless, so far advancing this combination further in the clinical trials …

… key challenges involved in the development of combination … vivo combination data, clinical
trials evaluating targeted drug … design and conduct of such studies are provided in Table 3. …